These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24571587)

  • 1. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
    Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
    Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.
    Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O
    Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
    Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
    Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 17 receptor in multiple sclerosis patients treated with interferon β-1a.
    Michałowska-Wender G; Biernacka-Łukanty J; Lasik Z; Jernas L; Wender M
    Folia Neuropathol; 2011; 49(2):138-41. PubMed ID: 21845543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-β regulates Th17 differentiation partly through the inhibition of osteopontin in experimental autoimmune encephalomyelitis.
    Zhao Q; Cheng W; Xi Y; Cao Z; Xu Y; Wu T; Li C; Niu X; Chen G
    Mol Immunol; 2018 Jan; 93():20-30. PubMed ID: 29127843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
    Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon β-1 therapy.
    Esendagli G; Kurne AT; Sayat G; Kilic AK; Guc D; Karabudak R
    J Neuroimmunol; 2013 Feb; 255(1-2):81-4. PubMed ID: 23177721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells.
    Sweeney CM; Lonergan R; Basdeo SA; Kinsella K; Dungan LS; Higgins SC; Kelly PJ; Costelloe L; Tubridy N; Mills KH; Fletcher JM
    Brain Behav Immun; 2011 Aug; 25(6):1170-81. PubMed ID: 21420486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
    Bălaşa R; Bajko Z; Huţanu A
    Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
    Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
    CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients.
    Jansson A; Ernerudh J; Kvarnström M; Ekerfelt C; Vrethem M
    Mult Scler; 2003 Oct; 9(5):440-5. PubMed ID: 14582766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
    Sega S; Wraber B; Mesec A; Horvat A; Ihan A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-7/IL-7 Receptor Signaling Differentially Affects Effector CD4+ T Cell Subsets Involved in Experimental Autoimmune Encephalomyelitis.
    Arbelaez CA; Glatigny S; Duhen R; Eberl G; Oukka M; Bettelli E
    J Immunol; 2015 Sep; 195(5):1974-83. PubMed ID: 26223651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis.
    Waubant E; Gee L; Miller K; Stabler G; Goodkin D
    J Interferon Cytokine Res; 2001 Mar; 21(3):181-5. PubMed ID: 11331041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.
    Milosevic E; Dujmovic I; Markovic M; Mesaros S; Rakocevic G; Drulovic J; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2015 Oct; 287():64-70. PubMed ID: 26439963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatigue favors in vitro Th1 and Th17-like cell expansion and reduces corticoid sensitivity in MS patients.
    Alvarenga-Filho H; Salles M; Hygino J; Ferreira TB; Sacramento PM; Monteiro C; Vasconcelos CC; Alvarenga RM; Bento CA
    J Neuroimmunol; 2017 Feb; 303():81-89. PubMed ID: 28065580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in circulating T cell functional subpopulations in interferon-beta treated multiple sclerosis patients: A pilot study.
    Monteiro A; Rosado P; Rosado L; Fonseca AM; Paiva A
    J Neuroimmunol; 2020 Feb; 339():577113. PubMed ID: 31778850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.